Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06749457 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

Study acronym: PEAK
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Trial sites reduced: 44 → 40 locations · Enrollment target: estimated 231 to confirmed 244 · Primary completion date: Apr 2, 2027 to Mar 8, 2027 · 4 more Show 7 more changesShow less
    • Trial sites reduced: 44 → 40 locations
    • Enrollment target: estimated 231 to confirmed 244
    • Primary completion date: Apr 2, 2027 to Mar 8, 2027
    • Completion date: Jan 7, 2028 to Dec 13, 2027
    • Eligibility criteria expanded, about 41 words
    • Secondary endpoints: details revised at 11 of 18 entries
    • Study description expanded, about 6 words
  2. Study sites: 43 to 44 Eligibility criteria expanded, about 68 words · Secondary endpoints: details revised at 8 of 18 entriesv21 Show 2 more changesShow less
    • Eligibility criteria expanded, about 68 words
    • Secondary endpoints: details revised at 8 of 18 entries

    See this version in full on ClinicalTrials.gov ↗

  3. Site details revised at 2 of 43 sitesv20
  4. Primary completion pushed from Nov 30, 2026 to Apr 2, 2027 Completion pushed from Sep 9, 2027 to Jan 7, 2028 · Study sites: 42 to 43v19 Show 2 more changesShow less
    • Completion pushed from Sep 9, 2027 to Jan 7, 2028
    • Study sites: 42 to 43
  5. Study sites: 41 to 42v18
  6. Primary completion pushed from Oct 9, 2026 to Nov 30, 2026 Completion pushed from Jul 6, 2027 to Sep 9, 2027 · Site details revised at 1 of 41 sitesv17 Show 2 more changesShow less
    • Completion pushed from Jul 6, 2027 to Sep 9, 2027
    • Site details revised at 1 of 41 sites
  7. Site details revised at 1 of 41 sitesv16
  8. Study sites: 40 to 41v15
  9. Site details revised at 1 of 40 sitesv14
  10. Site details revised at 2 of 40 sitesv13
  11. Site details revised at 10 of 40 sitesv12
  12. Site details revised at 13 of 40 sitesv11
  13. Study sites: 38 to 40v10
  14. Study sites: 34 to 38v9
  15. Study sites: 23 to 34 Study description shortened, about 11 words · Study arms: 6 to 7v8 Show 2 more changesShow less
    • Study description shortened, about 11 words
    • Study arms: 6 to 7

    See this version in full on ClinicalTrials.gov ↗

  16. Study sites: 20 to 23v7
  17. Study sites: 12 to 20v6
  18. Study sites: 5 to 12v5
  19. Study sites: 2 to 5v4
  20. Site details revised at 1 of 2 sitesv3
  21. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Secondary endpoints revised (18)v2 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Secondary endpoints revised (18)

    See this version in full on ClinicalTrials.gov ↗

  22. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
Trial Details
NCT Number NCT06749457
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Staphylococcus Aureus
Enrollment 244 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov